EP3603671A3 - Krebstammzellenspezifisches molekül - Google Patents
Krebstammzellenspezifisches molekül Download PDFInfo
- Publication number
- EP3603671A3 EP3603671A3 EP19191052.0A EP19191052A EP3603671A3 EP 3603671 A3 EP3603671 A3 EP 3603671A3 EP 19191052 A EP19191052 A EP 19191052A EP 3603671 A3 EP3603671 A3 EP 3603671A3
- Authority
- EP
- European Patent Office
- Prior art keywords
- cancer stem
- stem cells
- cell membrane
- membrane molecule
- antibody against
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 206010028980 Neoplasm Diseases 0.000 title abstract 7
- 201000011510 cancer Diseases 0.000 title abstract 7
- 210000000130 stem cell Anatomy 0.000 title abstract 7
- 210000000170 cell membrane Anatomy 0.000 abstract 4
- 101150017554 LGR5 gene Proteins 0.000 abstract 2
- 239000012830 cancer therapeutic Substances 0.000 abstract 1
- 210000004027 cell Anatomy 0.000 abstract 1
- 239000002458 cell surface marker Substances 0.000 abstract 1
- 239000003153 chemical reaction reagent Substances 0.000 abstract 1
- 210000002429 large intestine Anatomy 0.000 abstract 1
- 201000011061 large intestine cancer Diseases 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A61K39/001102—Receptors, cell surface antigens or cell surface determinants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/475—Growth factors; Growth regulators
- C07K14/51—Bone morphogenetic factor; Osteogenins; Osteogenic factor; Bone-inducing factor
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
- C07K16/3046—Stomach, Intestines
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6844—Nucleic acid amplification reactions
- C12Q1/686—Polymerase chain reaction [PCR]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
- C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57407—Specifically defined cancers
- G01N33/57419—Specifically defined cancers of colon
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
- G01N33/57492—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites involving compounds localized on the membrane of tumor or cancer cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55566—Emulsions, e.g. Freund's adjuvant, MF59
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/58—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation
- A61K2039/585—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation wherein the target is cancer
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
- C07K2317/41—Glycosylation, sialylation, or fucosylation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C07K2317/734—Complement-dependent cytotoxicity [CDC]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/158—Expression markers
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
- G01N2333/72—Assays involving receptors, cell surface antigens or cell surface determinants for hormones
- G01N2333/726—G protein coupled receptor, e.g. TSHR-thyrotropin-receptor, LH/hCG receptor, FSH
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Molecular Biology (AREA)
- Medicinal Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biochemistry (AREA)
- Oncology (AREA)
- Cell Biology (AREA)
- Genetics & Genomics (AREA)
- Microbiology (AREA)
- Biomedical Technology (AREA)
- Hematology (AREA)
- Urology & Nephrology (AREA)
- Analytical Chemistry (AREA)
- Biophysics (AREA)
- Pathology (AREA)
- Biotechnology (AREA)
- Zoology (AREA)
- Physics & Mathematics (AREA)
- Hospice & Palliative Care (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Wood Science & Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Physics & Mathematics (AREA)
- Food Science & Technology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Mycology (AREA)
- General Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Toxicology (AREA)
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2011237438 | 2011-10-28 | ||
JP2012091142 | 2012-04-12 | ||
EP12844389.2A EP2772268B8 (de) | 2011-10-28 | 2012-10-26 | Krebsstammzellenspezifisches molekül |
PCT/JP2012/077714 WO2013062083A1 (ja) | 2011-10-28 | 2012-10-26 | 癌幹細胞特異的分子 |
Related Parent Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP12844389.2A Division EP2772268B8 (de) | 2011-10-28 | 2012-10-26 | Krebsstammzellenspezifisches molekül |
EP12844389.2A Division-Into EP2772268B8 (de) | 2011-10-28 | 2012-10-26 | Krebsstammzellenspezifisches molekül |
Publications (2)
Publication Number | Publication Date |
---|---|
EP3603671A2 EP3603671A2 (de) | 2020-02-05 |
EP3603671A3 true EP3603671A3 (de) | 2020-07-29 |
Family
ID=48167907
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP19191052.0A Pending EP3603671A3 (de) | 2011-10-28 | 2012-10-26 | Krebstammzellenspezifisches molekül |
EP12844389.2A Active EP2772268B8 (de) | 2011-10-28 | 2012-10-26 | Krebsstammzellenspezifisches molekül |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP12844389.2A Active EP2772268B8 (de) | 2011-10-28 | 2012-10-26 | Krebsstammzellenspezifisches molekül |
Country Status (4)
Country | Link |
---|---|
US (3) | US20140302511A1 (de) |
EP (2) | EP3603671A3 (de) |
JP (6) | JP6291254B2 (de) |
WO (1) | WO2013062083A1 (de) |
Families Citing this family (16)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP2436397B1 (de) | 2009-05-29 | 2017-05-10 | Chugai Seiyaku Kabushiki Kaisha | Pharmazeutische zusammensetzung mit einem antagonisten eines liganden der egf-familie als bestandteil |
EP2517555A4 (de) | 2009-12-25 | 2014-09-24 | Chugai Pharmaceutical Co Ltd | Such- und screening-verfahren für ein zielmolekül eines krebsmittels mit einem nichtmenschlichen tiermodell mit darin transplantierter nog-krebszelllinie |
SG196836A1 (en) | 2010-10-06 | 2014-02-13 | Pharmalogicals Res Pte Ltd | Cancer stem cell population and method for production thereof |
DK2728002T3 (da) | 2011-06-30 | 2022-04-04 | Chugai Pharmaceutical Co Ltd | Heterodimeriseret polypeptid |
EP2749641B1 (de) | 2011-09-07 | 2021-06-02 | Chugai Seiyaku Kabushiki Kaisha | Krebsstammzellenisolierung |
JP6291254B2 (ja) | 2011-10-28 | 2018-03-14 | 中外製薬株式会社 | 癌幹細胞特異的分子 |
DK2817620T3 (en) * | 2012-02-22 | 2016-09-05 | Verik Bio Inc | IMMUNTERY TREATMENT SYSTEM FOR TUMOR FORMATION AND PROGRESSION |
EP2940135B9 (de) | 2012-12-27 | 2021-09-08 | Chugai Seiyaku Kabushiki Kaisha | Heterodimerisiertes polypeptid |
RU2016101716A (ru) * | 2013-06-24 | 2017-07-27 | Чугаи Сейяку Кабусики Кайся | Терапевтический агент, содержащий гуманизированное антиэпирегулиновое антитело в качестве действующего ингредиента для немелкоклеточной карциномы легкого, за исключением аденокарциномы |
WO2015198334A2 (en) * | 2014-06-25 | 2015-12-30 | Tel Hashomer Medical Research Infrastructure And Services Ltd. | Identification of cancer stem cells and use of same for diagnosis and treatment |
KR101779147B1 (ko) * | 2014-07-04 | 2017-09-20 | 연세대학교 산학협력단 | Kiaa1199를 이용한 췌장암의 진단 또는 치료용 조성물 |
JP2016028569A (ja) * | 2014-07-16 | 2016-03-03 | 学校法人慶應義塾 | がん幹細胞集団の調製方法、異種移植片の調製方法、スクリーニング方法、miR−34aの発現量を低下させる方法及びがん幹細胞増殖抑制剤 |
WO2017112811A1 (en) * | 2015-12-22 | 2017-06-29 | Abbvie Stemcentrx Llc | Novel anti-tnfsf9 antibodies and methods of use |
JPWO2018181276A1 (ja) | 2017-03-28 | 2020-02-06 | 学校法人慶應義塾 | ヒト組織幹細胞及びその使用 |
EP3835417A4 (de) * | 2018-08-08 | 2022-05-11 | Chugai Seiyaku Kabushiki Kaisha | Verfahren zur kultivierung von krebsgewebe oder gewebe analog zu krebsgewebe |
JP2023514727A (ja) | 2020-02-21 | 2023-04-07 | シルバーバック セラピューティックス インコーポレイテッド | ネクチン-4抗体コンジュゲートおよびその使用 |
Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2002012447A2 (en) * | 2000-08-03 | 2002-02-14 | Regents Of The University Of Michigan | Isolation and use of solid tumor stem cells |
US20080268476A1 (en) * | 2004-05-12 | 2008-10-30 | Institut National De La Sante Et De La Recherche Medicale (Inserm) | Nectin 4 (N4) as a Marker for Cancer Prognosis |
EP2070548A1 (de) * | 2006-10-12 | 2009-06-17 | Forerunner Pharma Research Co., Ltd. | Diagnose und behandlung von krebs mittels anti-ereg-antikörpern |
US20090214517A1 (en) * | 2004-07-27 | 2009-08-27 | Justin Wong | Compositions and methods of use for modulators of nectin 4, semaphorin 4b, igsf9, and kiaa0152 in treating disease |
WO2010067487A1 (en) * | 2008-12-12 | 2010-06-17 | Oncotherapy Science, Inc. | Nectin-4 for target genes of cancer therapy and diagnosis |
Family Cites Families (86)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS58201994A (ja) | 1982-05-21 | 1983-11-25 | Hideaki Hagiwara | 抗原特異的ヒト免疫グロブリンの生産方法 |
US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
DE3920358A1 (de) | 1989-06-22 | 1991-01-17 | Behringwerke Ag | Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung |
EP0585287B1 (de) | 1990-07-10 | 1999-10-13 | Cambridge Antibody Technology Limited | Verfahren zur herstellung von spezifischen bindungspaargliedern |
GB9015198D0 (en) | 1990-07-10 | 1990-08-29 | Brien Caroline J O | Binding substance |
EP0814159B1 (de) | 1990-08-29 | 2005-07-27 | GenPharm International, Inc. | Transgene Mäuse fähig zur Produktion heterologer Antikörper |
WO1993012227A1 (en) | 1991-12-17 | 1993-06-24 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
WO1993006213A1 (en) | 1991-09-23 | 1993-04-01 | Medical Research Council | Production of chimeric antibodies - a combinatorial approach |
WO1993011161A1 (en) | 1991-11-25 | 1993-06-10 | Enzon, Inc. | Multivalent antigen-binding proteins |
PT1024191E (pt) | 1991-12-02 | 2008-12-22 | Medical Res Council | Produção de auto-anticorpos a partir de reportórios de segmentos de anticorpo e exibidos em fagos |
EP0656941B1 (de) | 1992-03-24 | 2005-06-01 | Cambridge Antibody Technology Limited | Verfahren zur herstellung von gliedern von spezifischen bindungspaaren |
JPH07509137A (ja) | 1992-07-24 | 1995-10-12 | セル ジェネシス,インク. | 異種抗体の生産 |
US5573924A (en) * | 1992-09-08 | 1996-11-12 | Immunex Corporation | CD27 ligand |
US5648267A (en) | 1992-11-13 | 1997-07-15 | Idec Pharmaceuticals Corporation | Impaired dominant selectable marker sequence and intronic insertion strategies for enhancement of expression of gene product and expression vector systems comprising same |
EP0754225A4 (de) | 1993-04-26 | 2001-01-31 | Genpharm Int | Heterologe antikörper produzierende transgene nicht-humane tiere |
GB9313509D0 (en) | 1993-06-30 | 1993-08-11 | Medical Res Council | Chemisynthetic libraries |
AU690171B2 (en) | 1993-12-03 | 1998-04-23 | Medical Research Council | Recombinant binding proteins and peptides |
US5994524A (en) | 1994-07-13 | 1999-11-30 | Chugai Seiyaku Kabushiki Kaisha | Polynucleotides which encode reshaped IL-8-specific antibodies and methods to produce the same |
CN100335501C (zh) | 1996-09-26 | 2007-09-05 | 中外制药株式会社 | 抗人副甲状腺激素相关蛋白的抗体 |
DK2180007T4 (da) | 1998-04-20 | 2017-11-27 | Roche Glycart Ag | Glycosyleringsteknik for antistoffer til forbedring af antistofafhængig cellecytotoxicitet |
US6852318B1 (en) | 1998-05-08 | 2005-02-08 | The Regents Of The University Of California | Methods for detecting and inhibiting angiogenesis |
EP2275540B1 (de) | 1999-04-09 | 2016-03-23 | Kyowa Hakko Kirin Co., Ltd. | Verfahren zur Steuerung der Aktivität von immunologisch funktionellen Molekülen |
US8044259B2 (en) | 2000-08-03 | 2011-10-25 | The Regents Of The University Of Michigan | Determining the capability of a test compound to affect solid tumor stem cells |
US6946292B2 (en) | 2000-10-06 | 2005-09-20 | Kyowa Hakko Kogyo Co., Ltd. | Cells producing antibody compositions with increased antibody dependent cytotoxic activity |
MXPA03002974A (es) | 2000-10-06 | 2004-05-05 | Kyowa Hakko Kogyo Kk | Celulas que producen composiciones de anticuerpo. |
US7229960B2 (en) | 2000-11-03 | 2007-06-12 | University Of Vermont And State Agricultural College | Methods and compositions for inhibiting GRB7 |
EP1338198B1 (de) | 2000-12-01 | 2007-11-28 | Central Institute For Experimental Animals | Verfahren zur herstellung einer maus, die für die aufnahme, differenzierung und proliferation von heterogenen zellen geeignet ist, die hierdurch hergestellte maus und ihre verwendung |
US20030003097A1 (en) | 2001-04-02 | 2003-01-02 | Idec Pharmaceutical Corporation | Recombinant antibodies coexpressed with GnTIII |
WO2003104401A2 (en) * | 2002-06-05 | 2003-12-18 | Avalon Pharmaceuticals, Inc. | Cancer-linked gene as target for chemotherapy |
US7393531B2 (en) | 2003-01-21 | 2008-07-01 | Arius Research Inc. | Cytotoxicity mediation of cells evidencing surface expression of MCSP |
US20070053884A1 (en) | 2003-05-16 | 2007-03-08 | Kyowa Hakko Kogyo Co., Ltd | Novel adult tissue-derived stem cell and use thereof |
CA2447400A1 (en) | 2003-09-12 | 2005-03-12 | The Hospital For Sick Children | Brain tumor stem cells |
AU2004280064A1 (en) | 2003-10-09 | 2005-04-21 | Kyowa Hakko Kirin Co., Ltd. | Genomically modified cell neutralized to serum-free system |
JP2005206508A (ja) * | 2004-01-22 | 2005-08-04 | Chemo Sero Therapeut Res Inst | 悪性腫瘍細胞増殖抑制抗体 |
CN1980957A (zh) * | 2004-03-23 | 2007-06-13 | 比奥根艾迪克Ma公司 | 受体偶联剂及其治疗用途 |
US20080152700A1 (en) | 2004-06-01 | 2008-06-26 | Reza Sheikhnejad | Methods and compositions for the inhibition of gene expression |
JP2008514205A (ja) | 2004-09-29 | 2008-05-08 | 財団法人実験動物中央研究所 | Nogマウスを用いた高転移性細胞株の樹立 |
WO2006051405A2 (en) | 2004-11-12 | 2006-05-18 | Cambridge University Technical Services Ltd. | Methods and means related to cancer stem cells |
JPWO2006051984A1 (ja) | 2004-11-15 | 2008-05-29 | キリンファーマ株式会社 | 癌細胞の転移抑制方法およびそのために使用する医薬組成物 |
CA2605507C (en) * | 2005-04-19 | 2016-06-28 | Seattle Genetics, Inc. | Humanized anti-cd70 binding agents and uses thereof |
AU2006259583A1 (en) | 2005-06-13 | 2006-12-28 | The Regents Of The University Of Michigan | Compositions and methods for treating and diagnosing cancer |
CA2657886A1 (en) | 2005-07-26 | 2007-02-01 | Procure Therapeutics Limited | Stem cell markers |
JP2009509510A (ja) | 2005-09-26 | 2009-03-12 | メダレックス インコーポレーティッド | Cd70に対するヒトモノクローナル抗体 |
US20070220621A1 (en) | 2005-10-31 | 2007-09-20 | Clarke Michael F | Genetic characterization and prognostic significance of cancer stem cells in cancer |
AU2006308847C1 (en) | 2005-10-31 | 2012-05-10 | Oncomed Pharmaceuticals, Inc. | Compositions and methods for treating and diagnosing cancer |
EP1792979A1 (de) | 2005-12-01 | 2007-06-06 | Stiftung Caesar Center of Advanced European Studies and Research | Zellkultursystem für die Anreicherung und Expansion von Stammzellen |
CA2631931C (en) | 2005-12-01 | 2014-04-29 | Pronai Therapeutics, Inc. | Cancer therapies and pharmaceutical compositions used therein |
WO2007124125A2 (en) * | 2006-04-21 | 2007-11-01 | Stowers Institute For Medical Research | Methods of identifying stem cells in normal and cancerous tissues and related progeny cells |
WO2007132883A1 (ja) | 2006-05-17 | 2007-11-22 | Yokohama City University | 肝臓癌の鑑別、疾患ステージの判定又は予後の予測方法及びキット |
JP2009539374A (ja) | 2006-06-06 | 2009-11-19 | ユニバーシティ・オブ・テネシー・リサーチ・ファウンデーション | 腫瘍性幹細胞が富化された組成物及びそれを含む方法 |
WO2009045201A1 (en) * | 2006-08-02 | 2009-04-09 | Biogen Idec Ma Inc. | Cancer stem cells |
US8557584B2 (en) | 2006-08-11 | 2013-10-15 | Ao-Forschungsinstitut Davos | Preparing a homogenous population of stem cells committed to differentiated to a specific cell type |
EP2074144A4 (de) * | 2006-09-05 | 2011-03-16 | Medarex Inc | Antikörper gegen knochenmorphogene proteine und rezeptoren dafür und verfahren zu ihrer anwendung |
WO2008033393A2 (en) | 2006-09-11 | 2008-03-20 | University Of Florida | Isolation, expansion and uses of tumor stem cells |
GB2442059A (en) | 2006-09-19 | 2008-03-26 | Ist Superiore Sanita | Test for cancer of the gastrointestinal tract |
JP2008102012A (ja) | 2006-10-19 | 2008-05-01 | Kanazawa Univ | 癌幹細胞の同定および単離方法 |
EP2109668A4 (de) | 2007-01-22 | 2011-10-05 | Macrogenics West Inc | Menschliche krebsstammzellen |
JP2008182912A (ja) | 2007-01-29 | 2008-08-14 | Nippon Kayaku Co Ltd | 癌幹細胞の培養方法、および癌幹細胞 |
BRPI0811857A2 (pt) * | 2007-05-14 | 2014-10-21 | Biogen Idec Inc | Regiões fc (scfc) de cadeia simples, polipeptídeos de aglutinação que as compreendem e métodos relacionados. |
WO2008149803A1 (ja) | 2007-06-06 | 2008-12-11 | The University Of Tokyo | 表面抗原マーカーを用いた急性リンパ性白血病における癌幹細胞の分離同定方法 |
ES2553169T5 (es) | 2007-07-02 | 2023-11-30 | Oncomed Pharm Inc | Composiciones y métodos para el tratamiento y el diagnóstico del cáncer |
WO2009023194A2 (en) | 2007-08-10 | 2009-02-19 | Whitehead Institute For Biomedical Research | Hormone responsive tissue culture system and uses thereof |
EP2022848A1 (de) | 2007-08-10 | 2009-02-11 | Hubrecht Institut | Verfahren zur Identifikation, Vermehrung und Entfernung erwachsener Stammzellen und Krebsstammzellen |
GB2465940A (en) | 2007-10-01 | 2010-06-09 | Hospital For Sick Children | Neural tumor stem cells and methods of use thereof |
WO2009064301A1 (en) * | 2007-11-15 | 2009-05-22 | The Johns Hopkins University | Methods for detecting and monitoring circulating cancer stem cells |
JPWO2009078386A1 (ja) | 2007-12-14 | 2011-04-28 | 中外製薬株式会社 | 組織形態保持および核酸品質保持に優れた新規標本作製法 |
EP2271941B1 (de) | 2008-03-07 | 2012-08-08 | OSI Pharmaceuticals, Inc. | Verfahren zur identifizierung von mesenchymähnliche tumorzellen oder deren bildung hemmenden stoffen |
CN102076865B (zh) * | 2008-05-02 | 2016-03-16 | 西雅图基因公司 | 用于制造核心岩藻糖基化降低的抗体和抗体衍生物的方法和组合物 |
WO2010009121A2 (en) | 2008-07-15 | 2010-01-21 | University Of Florida Research Foundation, Inc. | Colon stem cells associated with colitis and colorectal cancer and methods of use |
WO2010016766A2 (en) | 2008-08-08 | 2010-02-11 | Koninklijke Nederlandse Akademie Van Wetenschappen | Antibodies recognizing endogenous human lgr5 and/or lgr6 |
EA201101241A1 (ru) * | 2009-03-06 | 2012-04-30 | Калобайос Фармасьютиклз, Инк. | Лечение лейкозов и хронических миелопролиферативных болезней антителами к ерна3 |
AU2010231575B2 (en) * | 2009-03-30 | 2013-09-12 | Edimer Biotech S.A. | Preparation of isolated agonist anti-EDAR monoclonal antibodies |
MA33323B1 (fr) * | 2009-04-20 | 2012-06-01 | Genentech Inc | Thérapie adjuvante de cancer |
TW201105347A (en) * | 2009-04-28 | 2011-02-16 | Chugai Pharmaceutical Co Ltd | Pharmaceutical compositions for maintenance therapy containing HLA class I-recognizing antibody as the active ingredient |
EP2436397B1 (de) * | 2009-05-29 | 2017-05-10 | Chugai Seiyaku Kabushiki Kaisha | Pharmazeutische zusammensetzung mit einem antagonisten eines liganden der egf-familie als bestandteil |
WO2011027308A1 (en) | 2009-09-03 | 2011-03-10 | Koninklijke Philips Electronics N.V. | Novel tumor markers |
EP2517555A4 (de) | 2009-12-25 | 2014-09-24 | Chugai Pharmaceutical Co Ltd | Such- und screening-verfahren für ein zielmolekül eines krebsmittels mit einem nichtmenschlichen tiermodell mit darin transplantierter nog-krebszelllinie |
US9217032B2 (en) | 2010-01-08 | 2015-12-22 | Les Laboratoires Servier | Methods for treating colorectal cancer |
SG196836A1 (en) | 2010-10-06 | 2014-02-13 | Pharmalogicals Res Pte Ltd | Cancer stem cell population and method for production thereof |
CN103477228A (zh) * | 2011-01-13 | 2013-12-25 | 延世大学校产学协力团 | 利用胰腺癌癌症干细胞特性的胰腺癌新型生物标记及用途 |
DK2728002T3 (da) | 2011-06-30 | 2022-04-04 | Chugai Pharmaceutical Co Ltd | Heterodimeriseret polypeptid |
EP2749641B1 (de) | 2011-09-07 | 2021-06-02 | Chugai Seiyaku Kabushiki Kaisha | Krebsstammzellenisolierung |
JP6291254B2 (ja) | 2011-10-28 | 2018-03-14 | 中外製薬株式会社 | 癌幹細胞特異的分子 |
TWI593705B (zh) | 2011-12-28 | 2017-08-01 | Chugai Pharmaceutical Co Ltd | Humanized anti-epiregulin antibody and cancer therapeutic agent containing the antibody as an active ingredient |
EP2940135B9 (de) | 2012-12-27 | 2021-09-08 | Chugai Seiyaku Kabushiki Kaisha | Heterodimerisiertes polypeptid |
US10504315B2 (en) | 2013-08-05 | 2019-12-10 | Ncr Corporation | Clamping of media items |
-
2012
- 2012-10-26 JP JP2013540843A patent/JP6291254B2/ja active Active
- 2012-10-26 EP EP19191052.0A patent/EP3603671A3/de active Pending
- 2012-10-26 WO PCT/JP2012/077714 patent/WO2013062083A1/ja active Application Filing
- 2012-10-26 US US14/354,517 patent/US20140302511A1/en not_active Abandoned
- 2012-10-26 EP EP12844389.2A patent/EP2772268B8/de active Active
-
2016
- 2016-02-12 US US15/042,548 patent/US10934351B2/en active Active
-
2017
- 2017-11-29 JP JP2017228927A patent/JP6580112B2/ja active Active
-
2019
- 2019-05-31 JP JP2019102325A patent/JP6794496B2/ja active Active
-
2020
- 2020-06-26 US US16/913,341 patent/US11858987B2/en active Active
- 2020-11-11 JP JP2020187991A patent/JP6985486B2/ja active Active
-
2021
- 2021-11-25 JP JP2021191088A patent/JP7335310B2/ja active Active
-
2023
- 2023-08-17 JP JP2023133133A patent/JP2023159269A/ja active Pending
Patent Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2002012447A2 (en) * | 2000-08-03 | 2002-02-14 | Regents Of The University Of Michigan | Isolation and use of solid tumor stem cells |
US20080268476A1 (en) * | 2004-05-12 | 2008-10-30 | Institut National De La Sante Et De La Recherche Medicale (Inserm) | Nectin 4 (N4) as a Marker for Cancer Prognosis |
US20090214517A1 (en) * | 2004-07-27 | 2009-08-27 | Justin Wong | Compositions and methods of use for modulators of nectin 4, semaphorin 4b, igsf9, and kiaa0152 in treating disease |
EP2070548A1 (de) * | 2006-10-12 | 2009-06-17 | Forerunner Pharma Research Co., Ltd. | Diagnose und behandlung von krebs mittels anti-ereg-antikörpern |
WO2010067487A1 (en) * | 2008-12-12 | 2010-06-17 | Oncotherapy Science, Inc. | Nectin-4 for target genes of cancer therapy and diagnosis |
Non-Patent Citations (1)
Title |
---|
ATSUSHI TAKANO ET AL: "Identification of Nectin-4 Oncoprotein as a Diagnostic and Therapeutic Target for Lung Cancer", CANCER RESEARCH, AMERICAN ASSOCIATION FOR CANCER RESEARCH, US, vol. 69, no. 16, 15 August 2009 (2009-08-15), pages 6694 - 6703, XP002637331, ISSN: 0008-5472, DOI: 10.1158/0008-5472.CAN-09-0016 * |
Also Published As
Publication number | Publication date |
---|---|
EP2772268A4 (de) | 2015-12-02 |
US11858987B2 (en) | 2024-01-02 |
US10934351B2 (en) | 2021-03-02 |
JP2021035971A (ja) | 2021-03-04 |
JP6794496B2 (ja) | 2020-12-02 |
US20160159904A1 (en) | 2016-06-09 |
EP2772268B8 (de) | 2020-01-08 |
JP2018083811A (ja) | 2018-05-31 |
JP6291254B2 (ja) | 2018-03-14 |
JP2023159269A (ja) | 2023-10-31 |
US20200325222A1 (en) | 2020-10-15 |
EP3603671A2 (de) | 2020-02-05 |
JP7335310B2 (ja) | 2023-08-29 |
JPWO2013062083A1 (ja) | 2015-04-02 |
JP2022028866A (ja) | 2022-02-16 |
JP6985486B2 (ja) | 2021-12-22 |
JP2019194190A (ja) | 2019-11-07 |
EP2772268B1 (de) | 2019-09-04 |
EP2772268A1 (de) | 2014-09-03 |
JP6580112B2 (ja) | 2019-09-25 |
US20140302511A1 (en) | 2014-10-09 |
WO2013062083A1 (ja) | 2013-05-02 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP3603671A3 (de) | Krebstammzellenspezifisches molekül | |
EA201590027A1 (ru) | Способы детекции заболеваний или состояний | |
EA201600085A1 (ru) | Набор для обнаружения соевого события syht0h2 | |
EP3955004A3 (de) | Verwendung von fettsäuren in verfahren zur krebserkennung | |
EP2596132A4 (de) | Verfahren zur erkennung von anzeichen für krankheiten oder leiden in körperflüssigkeiten | |
EA201390149A1 (ru) | Способы выявления заболевания или патологических состояний с использованием фагоцитарных клеток | |
SG195256A1 (en) | Alkylamino bodipy dyes as selective fluorescent probes for proteins andmouse embryonic stem cells | |
WO2014020502A3 (en) | Markers associated with sensitivity to inhibitors of human double minute 2 (mdm2) | |
WO2012096545A3 (ko) | 췌장암 암줄기세포 특성을 이용한 췌장암 신규 바이오마커 및 그의 용도 | |
MX347964B (es) | Metodos y kits para la deteccion de células tumorales circulantes en pacientes pancreáticos por medio del uso de captura poliespecífica y reactivos de detección de cocteles. | |
AR090017A1 (es) | Agonistas de fgfr1 y sus metodos de uso | |
GB2519906A (en) | Methods and systems for detecting biological components | |
EA201391245A1 (ru) | Интеррогативные клеточные анализы и их применение | |
NZ602369A (en) | Anti-cxcr1 compositions and methods | |
PH12014502436A1 (en) | In vitro method for the diagnosis and surveillance of cancer | |
BR112012021590A2 (pt) | detecção de capacitância em ensaio eletroquímico | |
NZ608316A (en) | Methods and compositions for diagnosis and prognosis of renal injury and renal failure | |
WO2012027266A3 (en) | Methods for dectecting embryonic stem cells, induced pluripotent stem cells, or cells undergoing reprogramming to produce induced pluripotent stem cells | |
AU2012339149A8 (en) | Method for the diagnosis of Niemann-Pick disease | |
AU2012236134A8 (en) | Biomarkers for predicting sensitivity to cancer treatments | |
BR112014031958A2 (pt) | bag3 como marcador de tecido e soro bioquímico | |
WO2012145516A3 (en) | Methods and kits for quantitative determination of total organic acid content in a coolant | |
GB201201766D0 (en) | Method | |
WO2013169931A3 (en) | Assays and cell-based tests using a receptor na/k-atpase/src complex and uses thereof | |
AU2013231230A8 (en) | Method for selecting or identifying a subject for V1B antagonist therapy |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: THE APPLICATION HAS BEEN PUBLISHED |
|
AC | Divisional application: reference to earlier application |
Ref document number: 2772268 Country of ref document: EP Kind code of ref document: P |
|
AK | Designated contracting states |
Kind code of ref document: A2 Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR |
|
PUAL | Search report despatched |
Free format text: ORIGINAL CODE: 0009013 |
|
AK | Designated contracting states |
Kind code of ref document: A3 Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR |
|
RIC1 | Information provided on ipc code assigned before grant |
Ipc: G01N 33/15 20060101ALI20200619BHEP Ipc: A61K 39/395 20060101AFI20200619BHEP Ipc: A61K 39/39 20060101ALI20200619BHEP Ipc: C07K 16/30 20060101ALI20200619BHEP Ipc: G01N 33/574 20060101ALI20200619BHEP Ipc: G01N 33/50 20060101ALI20200619BHEP Ipc: C07K 14/51 20060101ALI20200619BHEP Ipc: C12Q 1/68 20180101ALI20200619BHEP |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE |
|
17P | Request for examination filed |
Effective date: 20210128 |
|
RBV | Designated contracting states (corrected) |
Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: EXAMINATION IS IN PROGRESS |
|
17Q | First examination report despatched |
Effective date: 20230601 |